Introduction: Atrial high-rate episodes (AHREs) are associated with an increased risk of developing atrial fibrillation and thromboembolism. The characteristics of 'real world' patients developing AHREs are poorly known.

Methods: We included 496 consecutive patients with cardiac implantable electronic devices (CIEDs). Primary endpoint was occurrence of AHREs, defined as > 175 bpm and lasting > 5 min, in a median follow-up of 16.5 (IQR 3.9-38.6) months (1082.4 patient-years). We also tested the predictive value of clinical risk scores for AHREs.

Results: Mean age was 68.8 ± 14.0 years, and 35.5% were women; AHREs were recorded in 173 patients [34.7%, 16.0%/year, 95% confidence interval (CI) 13.7-18.6]. Multivariable Cox regression analysis showed that age [hazard ratio (HR) 1.020, 95% CI 1.004-1.035, p = 0.011], prior AF (HR 3.521, 95% CI 2.831-5.206, p < 0.001), white cell count (HR 1.039, 95% CI 1.007-1.072, p = 0.016) and high C reactive protein (CRP; HR 1.039, 95% CI 1.021-2.056, p = 0.038) were independently associated with AHREs. ROC curve analysis showed that the APPLE score (C statistic 0.53, 95% CI 0.48-0.59; p = 0.296) ALARMEc score (C statistic 0.51, 95% CI 0.44-0.57; p = 0.810) were non-significantly associated with AHRE. Similar results were obtained for CHADS and CHADSVASc score CONCLUSION: AHREs are common in CIEDs patients, with age, prior AF, inflammatory markers (high CRP, white cell count) being factors associated with AHREs onset. Clinical risk scores showed limited value for AHREs prediction in this cohort.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105258PMC
http://dx.doi.org/10.1007/s00392-018-1244-0DOI Listing

Publication Analysis

Top Keywords

atrial high-rate
8
high-rate episodes
8
episodes ahres
8
patients cardiac
8
cardiac implantable
8
implantable electronic
8
electronic devices
8
ahres
5
inflammation risk
4
risk atrial
4

Similar Publications

Interatrial Block and Atrial High-Rate Episodes.

Pacing Clin Electrophysiol

December 2024

Cardiology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, Madrid, Spain.

View Article and Find Full Text PDF

Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions.

Int J Cardiol

December 2024

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy; Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy. Electronic address:

With the increasing use of cardiac electronic implantable devices in recent years, the identification of asymptomatic atrial arrhythmias, including atrial high-rate episodes (AHREs) and device-detected subclinical atrial fibrillation (SCAF), has become common in clinical practice. AHREs have potentially important clinical implications because they are considered precursors of atrial fibrillation (AF). Although to a lesser extent than clinical AF, both AHREs and device-detected SCAF are associated with thromboembolic events, however routine use of anticoagulants in these conditions is not recommended.

View Article and Find Full Text PDF

Objective: Atrial high-rate episodes (AHRE) are atrial tachyarrhythmia episodes detected by implanted cardiac devices, characterised by an atrial rate exceeding 180-190 beats per minute. Recent studies have linked AHRE to the development of atrial fibrillation (AF) and increased stroke risk, especially when episodes last longer than 5-6 min. This study aimed to evaluate the relationship between predictive factors and the occurrence of AHRE in heart failure with reduced ejection fraction (HFrEF) patients with cardiac implantable electronic devices (CIEDs).

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the effect of conduction system pacing (CSP) on the occurrence of atrial high-rate episodes (AHREs) in heart failure patients with preserved ejection fraction (HFpEF), comparing it to right ventricular pacing (RVP).
  • Researchers analyzed data from 498 patients who received dual-chamber pacemakers between January 2018 and January 2023, noting both new-onset and progressive AHREs.
  • Findings indicate that CSP is associated with a significantly lower incidence of new-onset AHREs in patients without prior atrial fibrillation compared to RVP, and also showed improvements in various cardiac performance metrics following CSP.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!